Patent ID: 6632823
Filing Date: 2003-10-14
Classification: A61K,A61P,C07D

Abstract:
A compound having the Formula Z, as follows: or enantiomers, diastereomeric isomers or mixtures of any two or more thereof, or pharmaceutically acceptable salts thereof, wherein: each of R1, R2, R4 and R5, are independently hydrogen, halogen, cyano, cyanomethyl, nitro, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, heterocyclic, substituted heterocyclic, trifluoromethyl, pentafluoroethyl, â€”Oâ€”C(O)â€”RA, â€”Oâ€”C(O)â€”N(RA)2, â€”SRA, â€”NHC(O)RA or â€”NHSO2RA, wherein RA is H, lower alkyl, substituted lower alkyl, aryl or substituted aryl, or â€”NRBRB, wherein each RB is independently hydrogen or lower alkyl, wherein said substituted alkyl, substituted cycloalkyl, substituted alkenyl, substituted alkynyl, substituted aryl, substituted alkylaryl, substituted arylalkyl, and substituted heterocyclic are each optionally substituted with one or more substituents, each substituent independently is hydroxy, C1-4alkoxy, C1-4mercapto, aryl, heterocyclic, halogen, trifluoromethyl, pentafluoroethyl, cyano, cyanomethyl, nitro, amino, carboxyl, carbamate, or sulfonamide; D is optionally present; and when D is present, D is lower alkylene, substituted lower alkylene, cycloalkylene, substituted cycloalkylene, lower alkenylene, substituted lower alkenylene, or lower alkynylene; E is â€”C(O)â€”, â€”C(O)â€”NRCâ€”, â€”C(O)â€”Oâ€”, â€”Oâ€”C(O)â€”NRCâ€”, â€”Sâ€”, â€”S(O)â€”, â€”S(O)â€”NRCâ€”, â€”S(O)2â€”, â€”S(O)2â€”NRCâ€”or â€”S(O)&boxH;NHâ€”, wherein RC is hydrogen, lower alkyl or substituted lower alkyl; wherein when E is â€”Oâ€”C(O)â€”NRCâ€”, the oxygen is closest to the pyridine ring to which R1, R2, R4, and R5 are attached; G is optionally present; and when G is present, G is lower alkylene, substituted lower alkylene, lower alkenylene, substituted lower alkenylene or lower alkynylene; with the proviso that when E is â€”Sâ€”, G is not present or is â€”CH2â€”; with the proviso that when E is S or S(O)2, at least one of D or G is present; J is a dialkylamino group having the structure Jâ€²: wherein: RE and RF are independently hydrogen, lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl or cycloalkyl, or RE and RF combine to form a 3-7 membered ring, or J is a nitrogen-containing cyclic moiety having the structure Jâ€³: wherein R* is hydrogen, or one or both R* can cooperate with one another or with RD to form further ring(s), thereby forming polycyclic moieties containing fused rings having at least two atoms in common, m is 0-2, n is 0-3, X is optionally present, and when present is â€”Oâ€”, â€”CH2Oâ€”, â€”Sâ€”, â€”CH2Sâ€”, â€”S(O)â€”, â€”CH2S(O)â€”, â€”S(O)2â€”, â€”CH2S(O)2â€” or â€”CH2Nâ€”, and RD is hydrogen, lower alkyl or lower cycloalkyl, or RD is absent when the nitrogen atom to which it is attached participates in the formation of a double bond.